American International Group Inc. Grows Position in Spark Therapeutics Inc (ONCE)
American International Group Inc. increased its holdings in Spark Therapeutics Inc (NASDAQ:ONCE) by 23.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,862 shares of the biotechnology company’s stock after purchasing an additional 3,442 shares during the quarter. American International Group Inc.’s holdings in Spark Therapeutics were worth $1,593,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in ONCE. Teachers Advisors LLC raised its holdings in shares of Spark Therapeutics by 1.9% in the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after purchasing an additional 650 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Spark Therapeutics by 81.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock worth $1,507,000 after purchasing an additional 11,335 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Spark Therapeutics by 8.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 94,920 shares of the biotechnology company’s stock worth $5,671,000 after purchasing an additional 7,169 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Spark Therapeutics in the 2nd quarter worth approximately $829,000. Finally, Rhumbline Advisers raised its holdings in shares of Spark Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 26,278 shares of the biotechnology company’s stock worth $1,570,000 after purchasing an additional 3,626 shares in the last quarter. Institutional investors and hedge funds own 94.94% of the company’s stock.
Spark Therapeutics Inc (ONCE) opened at $45.91 on Thursday. Spark Therapeutics Inc has a 12 month low of $41.06 and a 12 month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.07) EPS. sell-side analysts expect that Spark Therapeutics Inc will post -7.6 earnings per share for the current fiscal year.
ONCE has been the topic of a number of research reports. ValuEngine downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. BMO Capital Markets reiterated a “buy” rating and issued a $101.00 target price on shares of Spark Therapeutics in a report on Wednesday, November 15th. Cantor Fitzgerald reiterated a “buy” rating and issued a $105.00 target price (up from $94.00) on shares of Spark Therapeutics in a report on Tuesday, October 10th. Goldman Sachs Group restated a “buy” rating and set a $111.00 price target on shares of Spark Therapeutics in a report on Friday, October 6th. Finally, Barclays boosted their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the company an “overweight” rating in a report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $79.14.
In other Spark Therapeutics news, insider Daniel Faga sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the transaction, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the completion of the transaction, the chief executive officer now owns 250,000 shares in the company, valued at approximately $17,885,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,068,809 shares of company stock worth $89,809,385. Company insiders own 7.30% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.